Success Metrics

Clinical Success Rate
55.6%

Based on 5 completed trials

Completion Rate
56%(5/9)
Active Trials
1(9%)
Results Posted
60%(3 trials)
Terminated
4(36%)

Phase Distribution

Ph phase_2
6
55%
Ph phase_3
2
18%
Ph phase_4
1
9%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
6(54.5%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(5)
Terminated(4)

Detailed Status

Completed5
Terminated4
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
55.6%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 26 (54.5%)
Phase 32 (18.2%)
Phase 41 (9.1%)

Trials by Status

not_yet_recruiting19%
completed545%
recruiting19%
terminated436%

Recent Activity

1 active trials
Showing 5 of 11
completedphase_1

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

NCT07435311
completedphase_3

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

NCT07435324
not_yet_recruitingphase_3

Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.

NCT07595276
recruitingphase_2

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

NCT05745857
completedphase_4

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

NCT01553032
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07435311Phase 1

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Completed
NCT07435324Phase 3

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Completed
NCT07595276Phase 3

Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.

Not Yet Recruiting
NCT05745857Phase 2

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Recruiting
NCT01553032Phase 4

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

Completed
NCT01102231Phase 2

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Completed
NCT00570674Phase 1

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Terminated
NCT01237483Phase 2

Reirradiation and Erbitux in the HNSCC

Completed
NCT01794845Phase 2

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Terminated
NCT00681876Phase 2

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Terminated
NCT00518193Phase 2

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11